NCBI Home Page NCBI Site Search page NCBI Guide that lists and describes the NCBI resources
Conserved domains on  [gi|2528347748|ref|WP_289151861|]
View 

aminopeptidase N [Porticoccus sp. W117]

Protein Classification

M1 family metallopeptidase( domain architecture ID 11487037)

M1 family metallopeptidase is a zinc-dependent metallopeptidase that functions as an aminopeptidase and contains an HEXXH motif as part of its active site; such as aminopeptidase N, which is a type II integral membrane protease that preferentially cleaves neutral amino acids from the N-terminus of oligopeptides

Graphical summary

 Zoom to residue level

show extra options »

Show site features     Horizontal zoom: ×

List of domain hits

Name Accession Description Interval E-value
pepN PRK14015
aminopeptidase N; Provisional
1-883 0e+00

aminopeptidase N; Provisional


:

Pssm-ID: 237585 [Multi-domain]  Cd Length: 875  Bit Score: 1634.46  E-value: 0e+00
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748   1 MKNAQPKTIYLKDYQPPNYLIDTTELRVELMEEGATVTATLKMRRNSHAGEDAPLLLHGIELELRELKIDGRVLDANEYY 80
Cdd:PRK14015    1 MRTQQPQAIYLKDYRPPDYLIDTVDLDFDLDPDKTRVTARLQVRRNPDAAHSAPLVLDGEDLELLSLALDGQPLAPSAYE 80
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748  81 ADAESLTIEQVPAEFVLESTVFIKPQENTSLEGLYKSDDMFCTQCEAEGFRKITYYLDRPDVMSEYTTTVVADKAGYPVL 160
Cdd:PRK14015   81 LDEEGLTIENLPDRFTLEIETEIDPEANTALEGLYRSGGMFCTQCEAEGFRRITYFLDRPDVLARYTVRIEADKAKYPVL 160
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 161 LSNGNPIDSGELDNGRHFVTWHDPFKKPSYLFALVAGDLEYIEDSFTTMSGRNIELRIFVEEKDIDKCDHAMRSLKKSMA 240
Cdd:PRK14015  161 LSNGNLVESGELPDGRHWATWEDPFPKPSYLFALVAGDLDVLEDTFTTRSGREVALEIYVEPGNLDKCDHAMDSLKKSMK 240
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 241 WDEEVYGREYDLDIFMIVAVDAFNMGAMENKGLNIFNTSAVLAKTETTTDAAFQRVEAIVAHEYFHNWSGNRVTCRDWFQ 320
Cdd:PRK14015  241 WDEERFGLEYDLDIFMIVAVDDFNMGAMENKGLNIFNSKYVLADPETATDADYERIESVIAHEYFHNWTGNRVTCRDWFQ 320
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 321 LSLKEGFTVFRDAEFSADMGSRVVKRVEDVSLLRTAQFSEDAGPMAHPVQPASFIEISNFYTLTVYEKGCEVVRMYHTLL 400
Cdd:PRK14015  321 LSLKEGLTVFRDQEFSADLGSRAVKRIEDVRVLRAAQFAEDAGPMAHPVRPDSYIEINNFYTATVYEKGAEVIRMLHTLL 400
                         410       420       430       440       450       460       470       480
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 401 GPELFREGSDLYFDRHDGQAATIEDFTRCMEEVSGRDLTQFKRWYSQAGTPRLDVNGSYDADAQTYTLNFAQSCPATPES 480
Cdd:PRK14015  401 GEEGFRKGMDLYFERHDGQAVTCEDFVAAMEDASGRDLSQFRRWYSQAGTPRVTVSDEYDAAAGTYTLTLSQSTPPTPGQ 480
                         490       500       510       520       530       540       550       560
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 481 AEKQPFHIPVTLGLVGQQG-DLPLTLQGVEQTEtytdmVLEITESEQSFVFENVTEQPVPSLLRDFSAPVKLDFPYSNAD 559
Cdd:PRK14015  481 PEKQPLHIPVAIGLLDPDGkELPLQLEGEPVER-----VLELTEAEQTFTFENVAERPVPSLLRGFSAPVKLEYDYSDED 555
                         570       580       590       600       610       620       630       640
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 560 LTFLMSRDSDGFNRWDACQKLATGILEGLVQAQldGATMELDSSLVAAFRTVLNDDSLDPAMVALMLKLPSEAYLAEEAD 639
Cdd:PRK14015  556 LLFLMAHDSDPFNRWEAGQRLATRLLLANVARH--GQPLSLDEALIDAFRAVLLDESLDPAFAAELLTLPSEAELAEQME 633
                         650       660       670       680       690       700       710       720
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 640 VIHVDEIHNAREFVRDQLAQQLKAEFQAAYDSNQVSEPYEPSAAQIAKRSLKNVALGYLMLADD-DAISLARSQYDNANN 718
Cdd:PRK14015  634 VIDPDAIHAAREALRRALATALKDELLALYEALQTDGPYSPDAEAAGRRALRNVCLSYLAAADDeEAAELAEAQFDQADN 713
                         730       740       750       760       770       780       790       800
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 719 MTDSAAALALLVCSDKPQAQhqaaELIIAFYEKWQQEALVVNQWFTVQAIAPQQGAVERVRELMQHPAFDIKNPNKVRSL 798
Cdd:PRK14015  714 MTDRLAALSALVNADLPERD----EALADFYDRWKDDPLVMDKWFALQATSPAPDTLERVRALMQHPAFDLKNPNRVRSL 789
                         810       820       830       840       850       860       870       880
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 799 IGAFCANNHVNFHRTDGAGYQLLADMVIELNTLNPQIAARLLAPLSKWQKQIPQRQQLMKEQLSRILATEELSKDVYEVV 878
Cdd:PRK14015  790 IGAFAAANPAGFHAADGSGYRFLADQILALDKINPQVAARLATPLIRWRRYDPKRQALMRAALERIAALPNLSKDVREIV 869

                  ....*
gi 2528347748 879 SKSLK 883
Cdd:PRK14015  870 SKALA 874
 
Name Accession Description Interval E-value
pepN PRK14015
aminopeptidase N; Provisional
1-883 0e+00

aminopeptidase N; Provisional


Pssm-ID: 237585 [Multi-domain]  Cd Length: 875  Bit Score: 1634.46  E-value: 0e+00
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748   1 MKNAQPKTIYLKDYQPPNYLIDTTELRVELMEEGATVTATLKMRRNSHAGEDAPLLLHGIELELRELKIDGRVLDANEYY 80
Cdd:PRK14015    1 MRTQQPQAIYLKDYRPPDYLIDTVDLDFDLDPDKTRVTARLQVRRNPDAAHSAPLVLDGEDLELLSLALDGQPLAPSAYE 80
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748  81 ADAESLTIEQVPAEFVLESTVFIKPQENTSLEGLYKSDDMFCTQCEAEGFRKITYYLDRPDVMSEYTTTVVADKAGYPVL 160
Cdd:PRK14015   81 LDEEGLTIENLPDRFTLEIETEIDPEANTALEGLYRSGGMFCTQCEAEGFRRITYFLDRPDVLARYTVRIEADKAKYPVL 160
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 161 LSNGNPIDSGELDNGRHFVTWHDPFKKPSYLFALVAGDLEYIEDSFTTMSGRNIELRIFVEEKDIDKCDHAMRSLKKSMA 240
Cdd:PRK14015  161 LSNGNLVESGELPDGRHWATWEDPFPKPSYLFALVAGDLDVLEDTFTTRSGREVALEIYVEPGNLDKCDHAMDSLKKSMK 240
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 241 WDEEVYGREYDLDIFMIVAVDAFNMGAMENKGLNIFNTSAVLAKTETTTDAAFQRVEAIVAHEYFHNWSGNRVTCRDWFQ 320
Cdd:PRK14015  241 WDEERFGLEYDLDIFMIVAVDDFNMGAMENKGLNIFNSKYVLADPETATDADYERIESVIAHEYFHNWTGNRVTCRDWFQ 320
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 321 LSLKEGFTVFRDAEFSADMGSRVVKRVEDVSLLRTAQFSEDAGPMAHPVQPASFIEISNFYTLTVYEKGCEVVRMYHTLL 400
Cdd:PRK14015  321 LSLKEGLTVFRDQEFSADLGSRAVKRIEDVRVLRAAQFAEDAGPMAHPVRPDSYIEINNFYTATVYEKGAEVIRMLHTLL 400
                         410       420       430       440       450       460       470       480
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 401 GPELFREGSDLYFDRHDGQAATIEDFTRCMEEVSGRDLTQFKRWYSQAGTPRLDVNGSYDADAQTYTLNFAQSCPATPES 480
Cdd:PRK14015  401 GEEGFRKGMDLYFERHDGQAVTCEDFVAAMEDASGRDLSQFRRWYSQAGTPRVTVSDEYDAAAGTYTLTLSQSTPPTPGQ 480
                         490       500       510       520       530       540       550       560
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 481 AEKQPFHIPVTLGLVGQQG-DLPLTLQGVEQTEtytdmVLEITESEQSFVFENVTEQPVPSLLRDFSAPVKLDFPYSNAD 559
Cdd:PRK14015  481 PEKQPLHIPVAIGLLDPDGkELPLQLEGEPVER-----VLELTEAEQTFTFENVAERPVPSLLRGFSAPVKLEYDYSDED 555
                         570       580       590       600       610       620       630       640
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 560 LTFLMSRDSDGFNRWDACQKLATGILEGLVQAQldGATMELDSSLVAAFRTVLNDDSLDPAMVALMLKLPSEAYLAEEAD 639
Cdd:PRK14015  556 LLFLMAHDSDPFNRWEAGQRLATRLLLANVARH--GQPLSLDEALIDAFRAVLLDESLDPAFAAELLTLPSEAELAEQME 633
                         650       660       670       680       690       700       710       720
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 640 VIHVDEIHNAREFVRDQLAQQLKAEFQAAYDSNQVSEPYEPSAAQIAKRSLKNVALGYLMLADD-DAISLARSQYDNANN 718
Cdd:PRK14015  634 VIDPDAIHAAREALRRALATALKDELLALYEALQTDGPYSPDAEAAGRRALRNVCLSYLAAADDeEAAELAEAQFDQADN 713
                         730       740       750       760       770       780       790       800
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 719 MTDSAAALALLVCSDKPQAQhqaaELIIAFYEKWQQEALVVNQWFTVQAIAPQQGAVERVRELMQHPAFDIKNPNKVRSL 798
Cdd:PRK14015  714 MTDRLAALSALVNADLPERD----EALADFYDRWKDDPLVMDKWFALQATSPAPDTLERVRALMQHPAFDLKNPNRVRSL 789
                         810       820       830       840       850       860       870       880
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 799 IGAFCANNHVNFHRTDGAGYQLLADMVIELNTLNPQIAARLLAPLSKWQKQIPQRQQLMKEQLSRILATEELSKDVYEVV 878
Cdd:PRK14015  790 IGAFAAANPAGFHAADGSGYRFLADQILALDKINPQVAARLATPLIRWRRYDPKRQALMRAALERIAALPNLSKDVREIV 869

                  ....*
gi 2528347748 879 SKSLK 883
Cdd:PRK14015  870 SKALA 874
pepN_proteo TIGR02414
aminopeptidase N, Escherichia coli type; The M1 family of zinc metallopeptidases contains a ...
13-882 0e+00

aminopeptidase N, Escherichia coli type; The M1 family of zinc metallopeptidases contains a number of distinct, well-separated clades of proteins with aminopeptidase activity. Several are designated aminopeptidase N, EC 3.4.11.2, after the Escherichia coli enzyme, suggesting a similar activity profile (see SP|P04825 for a description of catalytic activity). This family consists of all aminopeptidases closely related to E. coli PepN and presumed to have similar (not identical) function. Nearly all are found in Proteobacteria, but members are found also in Cyanobacteria, plants, and apicomplexan parasites. This family differs greatly in sequence from the family of aminopeptidases typified by Streptomyces lividans PepN (TIGR02412), from the membrane bound aminopeptidase N family in animals, etc. [Protein fate, Degradation of proteins, peptides, and glycopeptides]


Pssm-ID: 274122 [Multi-domain]  Cd Length: 863  Bit Score: 1415.16  E-value: 0e+00
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748  13 DYQPPNYLIDTTELRVELMEEGATVTATLKMRRNSHaGEDAPLLLHGIELELRELKIDGRVLDANEYYADAESLTIEQVP 92
Cdd:TIGR02414   1 DYKPPPFLIEKTHLDFDLHEEETVVRARLTVRRNPD-GNGAPLVLDGEELKLLSIAIDGKPLAAGDYQLDDETLTIASVP 79
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748  93 AEFVLESTVFIKPQENTSLEGLYKSDDMFCTQCEAEGFRKITYYLDRPDVMSEYTTTVVADKAGYPVLLSNGNPIDSGEL 172
Cdd:TIGR02414  80 ESFTLEIETEIHPEENTSLEGLYKSGGNFCTQCEAEGFRRITYFPDRPDVMSRYTVTITADKKKYPVLLSNGNKIASGEL 159
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 173 DNGRHFVTWHDPFKKPSYLFALVAGDLEYIEDSFTTMSGRNIELRIFVEEKDIDKCDHAMRSLKKSMAWDEEVYGREYDL 252
Cdd:TIGR02414 160 PDGRHWAEWEDPFPKPSYLFALVAGDLDVLEDTFTTKSGREVALRVYVEEGNKDKCDHAMESLKKAMKWDEEVFGLEYDL 239
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 253 DIFMIVAVDAFNMGAMENKGLNIFNTSAVLAKTETTTDAAFQRVEAIVAHEYFHNWSGNRVTCRDWFQLSLKEGFTVFRD 332
Cdd:TIGR02414 240 DIFMIVAVDDFNMGAMENKGLNIFNSKYVLADPETATDADYERIESVIAHEYFHNWTGNRVTCRDWFQLSLKEGLTVFRD 319
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 333 AEFSADMGSRVVKRVEDVSLLRTAQFSEDAGPMAHPVQPASFIEISNFYTLTVYEKGCEVVRMYHTLLGPELFREGSDLY 412
Cdd:TIGR02414 320 QEFSADMTSRAVKRIEDVRLLRAHQFPEDAGPMAHPVRPESYVEINNFYTATVYEKGAEVIRMLHTLLGEEGFRKGMDLY 399
                         410       420       430       440       450       460       470       480
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 413 FDRHDGQAATIEDFTRCMEEVSGRDLTQFKRWYSQAGTPRLDVNGSYDADAQTYTLNFAQSCPATPESAEKQPFHIPVTL 492
Cdd:TIGR02414 400 FSRHDGQAVTCEDFVAAMEDASGRDLNQFRRWYSQAGTPVLEVKENYDAAKKTYTLTVRQSTPPTPGQTEKKPLHIPIAV 479
                         490       500       510       520       530       540       550       560
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 493 GLVGQQG-DLPLTLQGVEQTETytdmVLEITESEQSFVFENVTEQPVPSLLRDFSAPVKLDFPYSNADLTFLMSRDSDGF 571
Cdd:TIGR02414 480 GLLGPNGrKLMLSLDGERDTTR----VLELTEAEQTFVFEGIAEKPVPSLLRGFSAPVNLEYPYSDEDLLLLLAHDSDPF 555
                         570       580       590       600       610       620       630       640
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 572 NRWDACQKLATGILEGLVQAQLDGATMELDSSLVAAFRTVLNDDSLDPAMVALMLKLPSEAYLAEEADVIHVDEIHNARE 651
Cdd:TIGR02414 556 NRWEAGQRLARRVILANIARAQGGEELPVDPAFIDALGKLLNDPHLDAAFKALLLALPSEAYLAELMENIDPDALHAARE 635
                         650       660       670       680       690       700       710       720
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 652 FVRDQLAQQLKAEFQAAYDSNQVSEPYEPSAAQIAKRSLKNVALGYLMLADD-DAISLARSQYDNANNMTDSAAALALLV 730
Cdd:TIGR02414 636 FLRAAIARQLADDLLRLYDALQENGPYSVDPAAAGRRALRNACLSYLSAADDaEIRNLALEQFKSADNMTDRLAALSALV 715
                         730       740       750       760       770       780       790       800
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 731 CSDKPqaqhQAAELIIAFYEKWQQEALVVNQWFTVQAIAPQQGAVERVRELMQHPAFDIKNPNKVRSLIGAFCANNHVNF 810
Cdd:TIGR02414 716 HFESD----FRERALAAFYQKWKDDPLVMDKWFALQATSPRPDTLERVKALLQHPAFDLKNPNRVRALIGAFANNNLVRF 791
                         810       820       830       840       850       860       870
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|..
gi 2528347748 811 HRTDGAGYQLLADMVIELNTLNPQIAARLLAPLSKWQKQIPQRQQLMKEQLSRILATEELSKDVYEVVSKSL 882
Cdd:TIGR02414 792 HDISGSGYRFLADQIIAIDRFNPQVAARLLEPLTRWRKLDPKRQELMKAALERIAAEENLSKDVREVVSKAL 863
M1_APN cd09600
Peptidase M1 family, including aminopeptidase N catalytic domain; This model represents the ...
13-446 0e+00

Peptidase M1 family, including aminopeptidase N catalytic domain; This model represents the catalytic domain of aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease belonging to the M1 gluzincin family. It includes bacterial-type alanyl aminopeptidases as well as PfA-M1 aminopeptidase (Plasmodium falciparum-type). APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and, in higher eukaryotes, is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation, thus considered a marker of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. APNs are also present in many pathogenic bacteria and represent potential drug targets. Some APNs have been used commercially, such as one from Lactococcus lactis used in the food industry. APN also serves as a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs have also been extensively studied as putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


Pssm-ID: 341063 [Multi-domain]  Cd Length: 434  Bit Score: 886.09  E-value: 0e+00
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748  13 DYQPPNYLIDTTELRVELMEEGATVTATLKMRRNSHAGEDAPLLLHGIELELRELKIDGRVLDANEYYADAESLTIEQVP 92
Cdd:cd09600     1 DYKPPDFLIDHVDLDFDLDDDETIVTSRLRVRRNPDSGEGAPLVLDGEDLELLSVKIDGKPLSPSDYTLDEEGLTIKNVP 80
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748  93 AEFVLESTVFIKPQENTSLEGLYKSDDMFCTQCEAEGFRKITYYLDRPDVMSEYTTTVVADKAGYPVLLSNGNPIDSGEL 172
Cdd:cd09600    81 DRFVLEIEVRINPAANTSLEGLYKSGGILCTQCEAEGFRRITYFPDRPDVMSKFTVTIEADKEKYPVLLSNGNLIEEGEL 160
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 173 DNGRHFVTWHDPFKKPSYLFALVAGDLEYIEDSFTTMSGRNIELRIFVEEKDIDKCDHAMRSLKKSMAWDEEVYGREYDL 252
Cdd:cd09600   161 PNGRHFAVWEDPFPKPSYLFALVAGDLGSVEDTFTTKSGRKVKLRIYVEPGNEDKCHHAMESLKKAMKWDEERFGLEYDL 240
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 253 DIFMIVAVDAFNMGAMENKGLNIFNTSAVLAKTETTTDAAFQRVEAIVAHEYFHNWSGNRVTCRDWFQLSLKEGFTVFRD 332
Cdd:cd09600   241 DLFNIVAVDDFNMGAMENKGLNIFNSKYVLADPETATDADYERIESVIAHEYFHNWTGNRVTCRDWFQLSLKEGLTVFRD 320
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 333 AEFSADMGSRVVKRVEDVSLLRTAQFSEDAGPMAHPVQPASFIEISNFYTLTVYEKGCEVVRMYHTLLGPELFREGSDLY 412
Cdd:cd09600   321 QEFSADMNSRAVKRIEDVRRLRSAQFPEDAGPMAHPIRPDSYIEINNFYTVTVYEKGAEVIRMLHTLLGEEGFRKGMDLY 400
                         410       420       430
                  ....*....|....*....|....*....|....
gi 2528347748 413 FDRHDGQAATIEDFTRCMEEVSGRDLTQFKRWYS 446
Cdd:cd09600   401 FERHDGQAVTCEDFVAAMEDASGRDLSQFKRWYS 434
PepN COG0308
Aminopeptidase N, contains DUF3458 domain [Amino acid transport and metabolism];
6-670 0e+00

Aminopeptidase N, contains DUF3458 domain [Amino acid transport and metabolism];


Pssm-ID: 440077 [Multi-domain]  Cd Length: 609  Bit Score: 550.79  E-value: 0e+00
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748   6 PKTIYLKDYQPPNYLIDTTELRVELMEEGATVTATLKMRRNSHAGEDAPLLLHGIELELRELKIDGRVLDaneYYADAES 85
Cdd:COG0308     2 KRLTRLEAYRPPGYDVTHYDLDLDLDPATTRLSGTATITFTATEAPLDSLVLDLKGLEVTSVTVDGKPLD---FTRDGER 78
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748  86 LTIE-----QVPAEFVLESTVFIKPQEntSLEGLYKS------DDMFCTQCEAEGFRkiTYYL--DRPDVMSEYTTTVVA 152
Cdd:COG0308    79 LTITlpkplAPGETFTLEIEYSGKPSN--GGEGLYRSgdppdgPPYLYTQCEPEGAR--RWFPcfDHPDDKATFTLTVTV 154
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 153 DKagYPVLLSNGNPIDSGELDNGRHFVTWHDPFKKPSYLFALVAGDLEYIEDSFttMSGrnIELRIFVEEKDIDKCDHAM 232
Cdd:COG0308   155 PA--GWVAVSNGNLVSETELGDGRTTWHWADTQPIPTYLFALAAGDYAVVEDTF--ASG--VPLRVYVRPGLADKAKEAF 228
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 233 RSLKKSMAWDEEVYGREYDLDIFMIVAVDAFNMGAMENKGLNIFNTSAVLakTETTTDAAFQRVEAIVAHEYFHNWSGNR 312
Cdd:COG0308   229 ESTKRMLDFFEELFGVPYPFDKYDQVAVPDFNFGAMENQGLVTFGEKVLA--DETATDADYERRESVIAHELAHQWFGNL 306
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 313 VTCRDWFQLSLKEGFTVFRDAEFSADMGSRVVKRVEDVSLLRTAQFSEDAGPMAHPVQPASFIEISNFYTLTVYEKGCEV 392
Cdd:COG0308   307 VTCADWDDLWLNEGFATYMEQLFSEDLYGKDAADRIFVGALRSYAFAEDAGPNAHPIRPDDYPEIENFFDGIVYEKGALV 386
                         410       420       430       440       450       460       470       480
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 393 VRMYHTLLGPELFREGSDLYFDRHDGQAATIEDFTRCMEEVSGRDLT-QFKRWYSQAGTPRLDVNGSYDADAQtYTLNFA 471
Cdd:COG0308   387 LHMLRTLLGDEAFRAGLRLYFARHAGGNATTEDFLAALEEASGRDLSaFFDQWLYQAGLPTLEVEYEYDADGK-VTLTLR 465
                         490       500       510       520       530       540       550       560
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 472 QscpatpESAEKQPFHIPVTLGLVGQQGDLPLTLQGVEQTEtytdmvleiteseqsfvfenVTEQPVPSLLrdfsapVKL 551
Cdd:COG0308   466 Q------TPPRPHPFHIPLEVGLLGGKLTARTVLLDGEQTE--------------------LVAKPDPVLL------LRL 513
                         570       580       590       600       610       620       630       640
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 552 DfpysnADLTFLMSRDSDGFNRWDACQKLAtgileglvqaqLDGatmelDSSLVAAFRTVLNDdslDPAMVALMLKLPSE 631
Cdd:COG0308   514 D-----DELAFLLAHDSDPFNRWEALQALW-----------RDG-----EADYLDALRALADT---DPAVRAEALALLGS 569
                         650       660       670
                  ....*....|....*....|....*....|....*....
gi 2528347748 632 aylaeeadvihvDEIHNAREFVRDQLAQQLKAEFQAAYD 670
Cdd:COG0308   570 ------------DQLALARAALALAAELALLRALDDLLA 596
DUF3458_C pfam17432
Domain of unknown function (DUF3458_C) ARM repeats; This presumed domain is functionally ...
558-883 2.79e-166

Domain of unknown function (DUF3458_C) ARM repeats; This presumed domain is functionally uncharacterized. This domain is found in bacteria, archaea and eukaryotes.


Pssm-ID: 465424 [Multi-domain]  Cd Length: 324  Bit Score: 486.25  E-value: 2.79e-166
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 558 ADLTFLMSRDSDGFNRWDACQKLATGILEGLVQAQLDGATMELDSSLVAAFRTVLNDDSLDPAMVALMLKLPSEAYLAEE 637
Cdd:pfam17432   2 EDLAFLLAHDSDPFNRWEAGQTLALRLLLALVAALQAGEPLALDAAFIDAFRAVLADAALDPAFKAEALTLPSEAYLAEQ 81
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 638 ADVIHVDEIHNAREFVRDQLAQQLKAEFQAAYDSNQVSEPYEPSAAQIAKRSLKNVALGYLMLADD-DAISLARSQYDNA 716
Cdd:pfam17432  82 MDVVDPDAIHAAREALRRALAEALRDELLALYQALAATGPYSPDAAAAGRRALRNLALSYLAAAGDpEAADLAAAQFESA 161
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 717 NNMTDSAAALALLVCSDKPQAQhqaaELIIAFYEKWQQEALVVNQWFTVQAIAPQQGAVERVRELMQHPAFDIKNPNKVR 796
Cdd:pfam17432 162 DNMTDRLAALAALVNSDLPERE----EALADFYQRWKDDPLVMDKWFALQATSPRPDTLERVKALMQHPAFDLKNPNRVR 237
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 797 SLIGAFCANNHVNFHRTDGAGYQLLADMVIELNTLNPQIAARLLAPLSKWQKQIPQRQQLMKEQLSRILATEELSKDVYE 876
Cdd:pfam17432 238 ALIGAFAAANPVAFHAADGSGYRFLADQVLELDAINPQVAARLLTPLTRWRRYDPPRQALMRAALERIAATPGLSKDVFE 317

                  ....*..
gi 2528347748 877 VVSKSLK 883
Cdd:pfam17432 318 IVSKALA 324
 
Name Accession Description Interval E-value
pepN PRK14015
aminopeptidase N; Provisional
1-883 0e+00

aminopeptidase N; Provisional


Pssm-ID: 237585 [Multi-domain]  Cd Length: 875  Bit Score: 1634.46  E-value: 0e+00
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748   1 MKNAQPKTIYLKDYQPPNYLIDTTELRVELMEEGATVTATLKMRRNSHAGEDAPLLLHGIELELRELKIDGRVLDANEYY 80
Cdd:PRK14015    1 MRTQQPQAIYLKDYRPPDYLIDTVDLDFDLDPDKTRVTARLQVRRNPDAAHSAPLVLDGEDLELLSLALDGQPLAPSAYE 80
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748  81 ADAESLTIEQVPAEFVLESTVFIKPQENTSLEGLYKSDDMFCTQCEAEGFRKITYYLDRPDVMSEYTTTVVADKAGYPVL 160
Cdd:PRK14015   81 LDEEGLTIENLPDRFTLEIETEIDPEANTALEGLYRSGGMFCTQCEAEGFRRITYFLDRPDVLARYTVRIEADKAKYPVL 160
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 161 LSNGNPIDSGELDNGRHFVTWHDPFKKPSYLFALVAGDLEYIEDSFTTMSGRNIELRIFVEEKDIDKCDHAMRSLKKSMA 240
Cdd:PRK14015  161 LSNGNLVESGELPDGRHWATWEDPFPKPSYLFALVAGDLDVLEDTFTTRSGREVALEIYVEPGNLDKCDHAMDSLKKSMK 240
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 241 WDEEVYGREYDLDIFMIVAVDAFNMGAMENKGLNIFNTSAVLAKTETTTDAAFQRVEAIVAHEYFHNWSGNRVTCRDWFQ 320
Cdd:PRK14015  241 WDEERFGLEYDLDIFMIVAVDDFNMGAMENKGLNIFNSKYVLADPETATDADYERIESVIAHEYFHNWTGNRVTCRDWFQ 320
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 321 LSLKEGFTVFRDAEFSADMGSRVVKRVEDVSLLRTAQFSEDAGPMAHPVQPASFIEISNFYTLTVYEKGCEVVRMYHTLL 400
Cdd:PRK14015  321 LSLKEGLTVFRDQEFSADLGSRAVKRIEDVRVLRAAQFAEDAGPMAHPVRPDSYIEINNFYTATVYEKGAEVIRMLHTLL 400
                         410       420       430       440       450       460       470       480
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 401 GPELFREGSDLYFDRHDGQAATIEDFTRCMEEVSGRDLTQFKRWYSQAGTPRLDVNGSYDADAQTYTLNFAQSCPATPES 480
Cdd:PRK14015  401 GEEGFRKGMDLYFERHDGQAVTCEDFVAAMEDASGRDLSQFRRWYSQAGTPRVTVSDEYDAAAGTYTLTLSQSTPPTPGQ 480
                         490       500       510       520       530       540       550       560
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 481 AEKQPFHIPVTLGLVGQQG-DLPLTLQGVEQTEtytdmVLEITESEQSFVFENVTEQPVPSLLRDFSAPVKLDFPYSNAD 559
Cdd:PRK14015  481 PEKQPLHIPVAIGLLDPDGkELPLQLEGEPVER-----VLELTEAEQTFTFENVAERPVPSLLRGFSAPVKLEYDYSDED 555
                         570       580       590       600       610       620       630       640
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 560 LTFLMSRDSDGFNRWDACQKLATGILEGLVQAQldGATMELDSSLVAAFRTVLNDDSLDPAMVALMLKLPSEAYLAEEAD 639
Cdd:PRK14015  556 LLFLMAHDSDPFNRWEAGQRLATRLLLANVARH--GQPLSLDEALIDAFRAVLLDESLDPAFAAELLTLPSEAELAEQME 633
                         650       660       670       680       690       700       710       720
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 640 VIHVDEIHNAREFVRDQLAQQLKAEFQAAYDSNQVSEPYEPSAAQIAKRSLKNVALGYLMLADD-DAISLARSQYDNANN 718
Cdd:PRK14015  634 VIDPDAIHAAREALRRALATALKDELLALYEALQTDGPYSPDAEAAGRRALRNVCLSYLAAADDeEAAELAEAQFDQADN 713
                         730       740       750       760       770       780       790       800
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 719 MTDSAAALALLVCSDKPQAQhqaaELIIAFYEKWQQEALVVNQWFTVQAIAPQQGAVERVRELMQHPAFDIKNPNKVRSL 798
Cdd:PRK14015  714 MTDRLAALSALVNADLPERD----EALADFYDRWKDDPLVMDKWFALQATSPAPDTLERVRALMQHPAFDLKNPNRVRSL 789
                         810       820       830       840       850       860       870       880
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 799 IGAFCANNHVNFHRTDGAGYQLLADMVIELNTLNPQIAARLLAPLSKWQKQIPQRQQLMKEQLSRILATEELSKDVYEVV 878
Cdd:PRK14015  790 IGAFAAANPAGFHAADGSGYRFLADQILALDKINPQVAARLATPLIRWRRYDPKRQALMRAALERIAALPNLSKDVREIV 869

                  ....*
gi 2528347748 879 SKSLK 883
Cdd:PRK14015  870 SKALA 874
pepN_proteo TIGR02414
aminopeptidase N, Escherichia coli type; The M1 family of zinc metallopeptidases contains a ...
13-882 0e+00

aminopeptidase N, Escherichia coli type; The M1 family of zinc metallopeptidases contains a number of distinct, well-separated clades of proteins with aminopeptidase activity. Several are designated aminopeptidase N, EC 3.4.11.2, after the Escherichia coli enzyme, suggesting a similar activity profile (see SP|P04825 for a description of catalytic activity). This family consists of all aminopeptidases closely related to E. coli PepN and presumed to have similar (not identical) function. Nearly all are found in Proteobacteria, but members are found also in Cyanobacteria, plants, and apicomplexan parasites. This family differs greatly in sequence from the family of aminopeptidases typified by Streptomyces lividans PepN (TIGR02412), from the membrane bound aminopeptidase N family in animals, etc. [Protein fate, Degradation of proteins, peptides, and glycopeptides]


Pssm-ID: 274122 [Multi-domain]  Cd Length: 863  Bit Score: 1415.16  E-value: 0e+00
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748  13 DYQPPNYLIDTTELRVELMEEGATVTATLKMRRNSHaGEDAPLLLHGIELELRELKIDGRVLDANEYYADAESLTIEQVP 92
Cdd:TIGR02414   1 DYKPPPFLIEKTHLDFDLHEEETVVRARLTVRRNPD-GNGAPLVLDGEELKLLSIAIDGKPLAAGDYQLDDETLTIASVP 79
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748  93 AEFVLESTVFIKPQENTSLEGLYKSDDMFCTQCEAEGFRKITYYLDRPDVMSEYTTTVVADKAGYPVLLSNGNPIDSGEL 172
Cdd:TIGR02414  80 ESFTLEIETEIHPEENTSLEGLYKSGGNFCTQCEAEGFRRITYFPDRPDVMSRYTVTITADKKKYPVLLSNGNKIASGEL 159
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 173 DNGRHFVTWHDPFKKPSYLFALVAGDLEYIEDSFTTMSGRNIELRIFVEEKDIDKCDHAMRSLKKSMAWDEEVYGREYDL 252
Cdd:TIGR02414 160 PDGRHWAEWEDPFPKPSYLFALVAGDLDVLEDTFTTKSGREVALRVYVEEGNKDKCDHAMESLKKAMKWDEEVFGLEYDL 239
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 253 DIFMIVAVDAFNMGAMENKGLNIFNTSAVLAKTETTTDAAFQRVEAIVAHEYFHNWSGNRVTCRDWFQLSLKEGFTVFRD 332
Cdd:TIGR02414 240 DIFMIVAVDDFNMGAMENKGLNIFNSKYVLADPETATDADYERIESVIAHEYFHNWTGNRVTCRDWFQLSLKEGLTVFRD 319
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 333 AEFSADMGSRVVKRVEDVSLLRTAQFSEDAGPMAHPVQPASFIEISNFYTLTVYEKGCEVVRMYHTLLGPELFREGSDLY 412
Cdd:TIGR02414 320 QEFSADMTSRAVKRIEDVRLLRAHQFPEDAGPMAHPVRPESYVEINNFYTATVYEKGAEVIRMLHTLLGEEGFRKGMDLY 399
                         410       420       430       440       450       460       470       480
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 413 FDRHDGQAATIEDFTRCMEEVSGRDLTQFKRWYSQAGTPRLDVNGSYDADAQTYTLNFAQSCPATPESAEKQPFHIPVTL 492
Cdd:TIGR02414 400 FSRHDGQAVTCEDFVAAMEDASGRDLNQFRRWYSQAGTPVLEVKENYDAAKKTYTLTVRQSTPPTPGQTEKKPLHIPIAV 479
                         490       500       510       520       530       540       550       560
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 493 GLVGQQG-DLPLTLQGVEQTETytdmVLEITESEQSFVFENVTEQPVPSLLRDFSAPVKLDFPYSNADLTFLMSRDSDGF 571
Cdd:TIGR02414 480 GLLGPNGrKLMLSLDGERDTTR----VLELTEAEQTFVFEGIAEKPVPSLLRGFSAPVNLEYPYSDEDLLLLLAHDSDPF 555
                         570       580       590       600       610       620       630       640
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 572 NRWDACQKLATGILEGLVQAQLDGATMELDSSLVAAFRTVLNDDSLDPAMVALMLKLPSEAYLAEEADVIHVDEIHNARE 651
Cdd:TIGR02414 556 NRWEAGQRLARRVILANIARAQGGEELPVDPAFIDALGKLLNDPHLDAAFKALLLALPSEAYLAELMENIDPDALHAARE 635
                         650       660       670       680       690       700       710       720
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 652 FVRDQLAQQLKAEFQAAYDSNQVSEPYEPSAAQIAKRSLKNVALGYLMLADD-DAISLARSQYDNANNMTDSAAALALLV 730
Cdd:TIGR02414 636 FLRAAIARQLADDLLRLYDALQENGPYSVDPAAAGRRALRNACLSYLSAADDaEIRNLALEQFKSADNMTDRLAALSALV 715
                         730       740       750       760       770       780       790       800
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 731 CSDKPqaqhQAAELIIAFYEKWQQEALVVNQWFTVQAIAPQQGAVERVRELMQHPAFDIKNPNKVRSLIGAFCANNHVNF 810
Cdd:TIGR02414 716 HFESD----FRERALAAFYQKWKDDPLVMDKWFALQATSPRPDTLERVKALLQHPAFDLKNPNRVRALIGAFANNNLVRF 791
                         810       820       830       840       850       860       870
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|..
gi 2528347748 811 HRTDGAGYQLLADMVIELNTLNPQIAARLLAPLSKWQKQIPQRQQLMKEQLSRILATEELSKDVYEVVSKSL 882
Cdd:TIGR02414 792 HDISGSGYRFLADQIIAIDRFNPQVAARLLEPLTRWRKLDPKRQELMKAALERIAAEENLSKDVREVVSKAL 863
M1_APN cd09600
Peptidase M1 family, including aminopeptidase N catalytic domain; This model represents the ...
13-446 0e+00

Peptidase M1 family, including aminopeptidase N catalytic domain; This model represents the catalytic domain of aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease belonging to the M1 gluzincin family. It includes bacterial-type alanyl aminopeptidases as well as PfA-M1 aminopeptidase (Plasmodium falciparum-type). APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and, in higher eukaryotes, is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation, thus considered a marker of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. APNs are also present in many pathogenic bacteria and represent potential drug targets. Some APNs have been used commercially, such as one from Lactococcus lactis used in the food industry. APN also serves as a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs have also been extensively studied as putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


Pssm-ID: 341063 [Multi-domain]  Cd Length: 434  Bit Score: 886.09  E-value: 0e+00
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748  13 DYQPPNYLIDTTELRVELMEEGATVTATLKMRRNSHAGEDAPLLLHGIELELRELKIDGRVLDANEYYADAESLTIEQVP 92
Cdd:cd09600     1 DYKPPDFLIDHVDLDFDLDDDETIVTSRLRVRRNPDSGEGAPLVLDGEDLELLSVKIDGKPLSPSDYTLDEEGLTIKNVP 80
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748  93 AEFVLESTVFIKPQENTSLEGLYKSDDMFCTQCEAEGFRKITYYLDRPDVMSEYTTTVVADKAGYPVLLSNGNPIDSGEL 172
Cdd:cd09600    81 DRFVLEIEVRINPAANTSLEGLYKSGGILCTQCEAEGFRRITYFPDRPDVMSKFTVTIEADKEKYPVLLSNGNLIEEGEL 160
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 173 DNGRHFVTWHDPFKKPSYLFALVAGDLEYIEDSFTTMSGRNIELRIFVEEKDIDKCDHAMRSLKKSMAWDEEVYGREYDL 252
Cdd:cd09600   161 PNGRHFAVWEDPFPKPSYLFALVAGDLGSVEDTFTTKSGRKVKLRIYVEPGNEDKCHHAMESLKKAMKWDEERFGLEYDL 240
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 253 DIFMIVAVDAFNMGAMENKGLNIFNTSAVLAKTETTTDAAFQRVEAIVAHEYFHNWSGNRVTCRDWFQLSLKEGFTVFRD 332
Cdd:cd09600   241 DLFNIVAVDDFNMGAMENKGLNIFNSKYVLADPETATDADYERIESVIAHEYFHNWTGNRVTCRDWFQLSLKEGLTVFRD 320
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 333 AEFSADMGSRVVKRVEDVSLLRTAQFSEDAGPMAHPVQPASFIEISNFYTLTVYEKGCEVVRMYHTLLGPELFREGSDLY 412
Cdd:cd09600   321 QEFSADMNSRAVKRIEDVRRLRSAQFPEDAGPMAHPIRPDSYIEINNFYTVTVYEKGAEVIRMLHTLLGEEGFRKGMDLY 400
                         410       420       430
                  ....*....|....*....|....*....|....
gi 2528347748 413 FDRHDGQAATIEDFTRCMEEVSGRDLTQFKRWYS 446
Cdd:cd09600   401 FERHDGQAVTCEDFVAAMEDASGRDLSQFKRWYS 434
PepN COG0308
Aminopeptidase N, contains DUF3458 domain [Amino acid transport and metabolism];
6-670 0e+00

Aminopeptidase N, contains DUF3458 domain [Amino acid transport and metabolism];


Pssm-ID: 440077 [Multi-domain]  Cd Length: 609  Bit Score: 550.79  E-value: 0e+00
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748   6 PKTIYLKDYQPPNYLIDTTELRVELMEEGATVTATLKMRRNSHAGEDAPLLLHGIELELRELKIDGRVLDaneYYADAES 85
Cdd:COG0308     2 KRLTRLEAYRPPGYDVTHYDLDLDLDPATTRLSGTATITFTATEAPLDSLVLDLKGLEVTSVTVDGKPLD---FTRDGER 78
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748  86 LTIE-----QVPAEFVLESTVFIKPQEntSLEGLYKS------DDMFCTQCEAEGFRkiTYYL--DRPDVMSEYTTTVVA 152
Cdd:COG0308    79 LTITlpkplAPGETFTLEIEYSGKPSN--GGEGLYRSgdppdgPPYLYTQCEPEGAR--RWFPcfDHPDDKATFTLTVTV 154
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 153 DKagYPVLLSNGNPIDSGELDNGRHFVTWHDPFKKPSYLFALVAGDLEYIEDSFttMSGrnIELRIFVEEKDIDKCDHAM 232
Cdd:COG0308   155 PA--GWVAVSNGNLVSETELGDGRTTWHWADTQPIPTYLFALAAGDYAVVEDTF--ASG--VPLRVYVRPGLADKAKEAF 228
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 233 RSLKKSMAWDEEVYGREYDLDIFMIVAVDAFNMGAMENKGLNIFNTSAVLakTETTTDAAFQRVEAIVAHEYFHNWSGNR 312
Cdd:COG0308   229 ESTKRMLDFFEELFGVPYPFDKYDQVAVPDFNFGAMENQGLVTFGEKVLA--DETATDADYERRESVIAHELAHQWFGNL 306
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 313 VTCRDWFQLSLKEGFTVFRDAEFSADMGSRVVKRVEDVSLLRTAQFSEDAGPMAHPVQPASFIEISNFYTLTVYEKGCEV 392
Cdd:COG0308   307 VTCADWDDLWLNEGFATYMEQLFSEDLYGKDAADRIFVGALRSYAFAEDAGPNAHPIRPDDYPEIENFFDGIVYEKGALV 386
                         410       420       430       440       450       460       470       480
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 393 VRMYHTLLGPELFREGSDLYFDRHDGQAATIEDFTRCMEEVSGRDLT-QFKRWYSQAGTPRLDVNGSYDADAQtYTLNFA 471
Cdd:COG0308   387 LHMLRTLLGDEAFRAGLRLYFARHAGGNATTEDFLAALEEASGRDLSaFFDQWLYQAGLPTLEVEYEYDADGK-VTLTLR 465
                         490       500       510       520       530       540       550       560
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 472 QscpatpESAEKQPFHIPVTLGLVGQQGDLPLTLQGVEQTEtytdmvleiteseqsfvfenVTEQPVPSLLrdfsapVKL 551
Cdd:COG0308   466 Q------TPPRPHPFHIPLEVGLLGGKLTARTVLLDGEQTE--------------------LVAKPDPVLL------LRL 513
                         570       580       590       600       610       620       630       640
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 552 DfpysnADLTFLMSRDSDGFNRWDACQKLAtgileglvqaqLDGatmelDSSLVAAFRTVLNDdslDPAMVALMLKLPSE 631
Cdd:COG0308   514 D-----DELAFLLAHDSDPFNRWEALQALW-----------RDG-----EADYLDALRALADT---DPAVRAEALALLGS 569
                         650       660       670
                  ....*....|....*....|....*....|....*....
gi 2528347748 632 aylaeeadvihvDEIHNAREFVRDQLAQQLKAEFQAAYD 670
Cdd:COG0308   570 ------------DQLALARAALALAAELALLRALDDLLA 596
DUF3458_C pfam17432
Domain of unknown function (DUF3458_C) ARM repeats; This presumed domain is functionally ...
558-883 2.79e-166

Domain of unknown function (DUF3458_C) ARM repeats; This presumed domain is functionally uncharacterized. This domain is found in bacteria, archaea and eukaryotes.


Pssm-ID: 465424 [Multi-domain]  Cd Length: 324  Bit Score: 486.25  E-value: 2.79e-166
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 558 ADLTFLMSRDSDGFNRWDACQKLATGILEGLVQAQLDGATMELDSSLVAAFRTVLNDDSLDPAMVALMLKLPSEAYLAEE 637
Cdd:pfam17432   2 EDLAFLLAHDSDPFNRWEAGQTLALRLLLALVAALQAGEPLALDAAFIDAFRAVLADAALDPAFKAEALTLPSEAYLAEQ 81
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 638 ADVIHVDEIHNAREFVRDQLAQQLKAEFQAAYDSNQVSEPYEPSAAQIAKRSLKNVALGYLMLADD-DAISLARSQYDNA 716
Cdd:pfam17432  82 MDVVDPDAIHAAREALRRALAEALRDELLALYQALAATGPYSPDAAAAGRRALRNLALSYLAAAGDpEAADLAAAQFESA 161
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 717 NNMTDSAAALALLVCSDKPQAQhqaaELIIAFYEKWQQEALVVNQWFTVQAIAPQQGAVERVRELMQHPAFDIKNPNKVR 796
Cdd:pfam17432 162 DNMTDRLAALAALVNSDLPERE----EALADFYQRWKDDPLVMDKWFALQATSPRPDTLERVKALMQHPAFDLKNPNRVR 237
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 797 SLIGAFCANNHVNFHRTDGAGYQLLADMVIELNTLNPQIAARLLAPLSKWQKQIPQRQQLMKEQLSRILATEELSKDVYE 876
Cdd:pfam17432 238 ALIGAFAAANPVAFHAADGSGYRFLADQVLELDAINPQVAARLLTPLTRWRRYDPPRQALMRAALERIAATPGLSKDVFE 317

                  ....*..
gi 2528347748 877 VVSKSLK 883
Cdd:pfam17432 318 IVSKALA 324
M1 cd09595
Peptidase M1 family includes the catalytic domains of aminopeptidase N and leukotriene A4 ...
36-432 3.20e-118

Peptidase M1 family includes the catalytic domains of aminopeptidase N and leukotriene A4 hydrolase; The model represents the catalytic domains of M1 peptidase family members including aminopeptidase N (APN) and leukotriene A4 hydrolase (LTA4H). All peptidases in this family bind a single catalytic zinc ion which is tetrahedrally co-ordinated by three amino acid ligands and a water molecule that forms the nucleophile upon activation during catalysis. APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and is present in a variety of human tissues and cell types. APN expression is dysregulated in many inflammatory diseases and is enhanced in numerous tumor cells, making it a lead target in the development of anti-cancer and anti-inflammatory drugs. LTA4H is a bifunctional enzyme, possessing an aminopeptidase as well as an epoxide hydrolase activity. The two activities occupy different, but overlapping sites. The activity and physiological relevance of the aminopeptidase in LTA4H is as yet unknown, while the epoxide hydrolase converts leukotriene A4 (LTA4) into leukotriene B4 (LTB4), a potent chemotaxin that is fundamental to the inflammatory response of mammals.


Pssm-ID: 341058 [Multi-domain]  Cd Length: 413  Bit Score: 365.61  E-value: 3.20e-118
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748  36 TVTATLKMRrNSHAGEdaPLLLHGIELELRELKIDGRVLD-ANEYYADAESLTI---EQVPAEFVLESTVFIKPQENTSL 111
Cdd:cd09595    17 NGTETLTVD-ASQVGR--ELVLDLVGLTIHSVSVNGAAVDfGEREHYDGEKLTIpgpKPPGQTFTVRISFEAKPSKNLLG 93
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 112 ----EGLYKSDDMFCTQCEAEGFRKITYYLDRPDVMSEYTTTVVADKagYPVLLSNGNPIDSGELDNGRHFVTWHDPFKK 187
Cdd:cd09595    94 wlweQTAGKEKPYLFTQFEATHARRIFPCIDHPAVKATFTVTITTPK--KDLLASNGALVGEETGANGRKTYRFEDTPPI 171
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 188 PSYLFALVAGDLEYIEDSFTTMsgRNIELRIFVEEKDIDKCDHAMRSLKKSMAWDEEVYGREYDLDIFMIVAVDAFNMGA 267
Cdd:cd09595   172 PTYLVAVVVGDLEFKYVTVKSQ--PRVGLSVYSEPLQVDQAQYAFDATRAALAWFEDYFGGPYPLPKYDLLAVPDFNSGA 249
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 268 MENKGLNIFNTSAVLAKTETttDAAFQRVEAIVAHEYFHNWSGNRVTCRDWFQLSLKEGFTVFRDAEFSADMG---SRVV 344
Cdd:cd09595   250 MENPGLITFRTTYLLRSKVT--DTGARSIENVIAHELAHQWFGNLVTMRWWNDLWLNEGFAVYYENRIMDATFgtsSRHL 327
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 345 KRVEDVSLLRTAQFSEDAGPMAHPVQpaSFIEISNFYTLTVYEKGCEVVRMYHTLLGPELFREGSDLYFDRHDGQAATIE 424
Cdd:cd09595   328 DQLSGSSDLNTEQLLEDSSPTSTPVR--SPADPDVAYDGVTYAKGALVLRMLEELVGEEAFDKGVQAYFNRHKFKNATTD 405

                  ....*...
gi 2528347748 425 DFTRCMEE 432
Cdd:cd09595   406 DFIDALEE 413
Peptidase_M1 pfam01433
Peptidase family M1 domain; Members of this family are aminopeptidases. The members differ ...
231-444 1.15e-53

Peptidase family M1 domain; Members of this family are aminopeptidases. The members differ widely in specificity, hydrolysing acidic, basic or neutral N-terminal residues. This family includes leukotriene-A4 hydrolase, this enzyme also has an aminopeptidase activity.


Pssm-ID: 426262 [Multi-domain]  Cd Length: 219  Bit Score: 185.96  E-value: 1.15e-53
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 231 AMRSLKKSMAWDEEVYGREYDLDIFMIVAVDAFNMGAMENKGLNIFNTSAVLAKTETTTDAAFQRVEAIVAHEYFHNWSG 310
Cdd:pfam01433   2 ALEITVKLLEFYEDYFNIPYPLPKYDLVALPDFSAGAMENWGLITYRETLLLYDPGNSSTSDKQRVASVIAHELAHQWFG 81
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 311 NRVTCRDWFQLSLKEGFTVFRDAEFSADMGSRVVKRVEDVSLLRTAQFSEDAGPMAHPVQ--PASFIEISNFYTLTVYEK 388
Cdd:pfam01433  82 NLVTMKWWDDLWLNEGFATYMEYLGTDALFPEWNIWEQFLLDEVQNAMARDALDSSHPITqnVNDPSEIDDIFDAIPYEK 161
                         170       180       190       200       210
                  ....*....|....*....|....*....|....*....|....*....|....*...
gi 2528347748 389 GCEVVRMYHTLLGPELFREGSDLYFDRHDGQAATIEDFTRCMEEVSGR-DLTQF-KRW 444
Cdd:pfam01433 162 GASVLRMLETLLGEEVFQKGLRSYLKKFQYGNATTEDLWDALSEASGPlDVDSFmDTW 219
M1_APN-Q_like cd09601
Peptidase M1 aminopeptidase N catalytic domain family which includes aminopeptidase N (APN), ...
57-439 1.29e-50

Peptidase M1 aminopeptidase N catalytic domain family which includes aminopeptidase N (APN), aminopeptidase Q (APQ), tricorn interacting factor F3, and endoplasmic reticulum aminopeptidase 1 (ERAP1); This M1 peptidase family includes eukaryotic and bacterial members: the catalytic domains of aminopeptidase N (APN), aminopeptidase Q (APQ, laeverin), endoplasmic reticulum aminopeptidase 1 (ERAP1) as well as tricorn interacting factor F3. Aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease, preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is considered a marker of differentiation since it is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. ERAP1, also known as endoplasmic reticulum aminopeptidase associated with antigen processing (ERAAP), adipocyte derived leucine aminopeptidase (A-LAP), or aminopeptidase regulating tumor necrosis factor receptor I (THFRI) shedding (ARTS-1), associates with the closely related ER aminopeptidase ERAP2, for the final trimming of peptides within the ER for presentation by MHC class I molecules. ERAP1 is associated with ankylosing spondylitis (AS), an inflammatory arthritis that predominantly affects the spine. ERAP1 also aids in the shedding of membrane-bound cytokine receptors. The tricorn interacting factor F3, together with factors F1 and F2, degrades the tricorn protease products, producing free amino acids, thus completing the proteasomal degradation pathway. F3 is homologous to F2, but not F1, and shows a strong preference for glutamate in the P1' position. APQ, also known as laeverin, is specifically expressed in human embryo-derived extravillous trophoblasts (EVTs) that invade the uterus during early placentation. It cleaves the N-terminal amino acid of various peptides such as angiotensin III, endokinin C, and kisspeptin-10, all expressed in the placenta in large quantities. APN is a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs are also putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


Pssm-ID: 341064 [Multi-domain]  Cd Length: 442  Bit Score: 184.71  E-value: 1.29e-50
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748  57 LHGIELELRELKIDGRVLDANEYYADAESLTIEQVpaEFVLESTvfIKPQE------------NTSLEGLYKS---DD-- 119
Cdd:cd09601    35 LHAKDLTITSASLTLKGGSGIIEVTVVTDEETEFL--TITLDET--LPPGEnytlsieftgklNDDLRGFYRSsytDEdg 110
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 120 ----MFCTQCEAEGFRKItyY--LDRPDVMSEYTTTVVADKaGYPVLlSNGNPIDSGELDNGRhfVTWHdpFKK----PS 189
Cdd:cd09601   111 etryLAATQFEPTDARRA--FpcFDEPAFKATFDITITHPK-GYTAL-SNMPPVESTELEDGW--KTTT--FETtppmST 182
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 190 YLFALVAGDLEYIEdsftTMSGRNIELRIFVEEKDIDKCDHAMRSLKKSMAWDEEVYGREYDL---DIfmiVAVDAFNMG 266
Cdd:cd09601   183 YLVAFVVGDFEYIE----STTKSGVPVRVYARPGKIEQGDFALEVAPKILDFYEDYFGIPYPLpklDL---VAIPDFAAG 255
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 267 AMENKGLNIFNTSAVLAKTETTTDAAFQRVEAIVAHEYFHNWSGNRVTCRDWFQLSLKEGFtvfrdAEFsadMGSRVVK- 345
Cdd:cd09601   256 AMENWGLITYRETALLYDPKTSSASDKQRVAEVIAHELAHQWFGNLVTMKWWDDLWLNEGF-----ATY---MEYLAVDk 327
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 346 -----RVEDVSLLRTAQ--FSEDAGPMAHPVQPA--SFIEISNFYTLTVYEKGCEVVRMYHTLLGPELFREGSDLYFDRH 416
Cdd:cd09601   328 lfpewNMWDQFVVDELQsaLELDSLASSHPIEVPveSPSEISEIFDAISYSKGASVLRMLENFLGEEVFRKGLRKYLKKH 407
                         410       420
                  ....*....|....*....|...
gi 2528347748 417 DGQAATIEDFTRCMEEVSGRDLT 439
Cdd:cd09601   408 AYGNATTDDLWEALQEASGESKP 430
DUF3458 pfam11940
Domain of unknown function (DUF3458) Ig-like fold; This presumed domain is functionally ...
449-554 7.10e-42

Domain of unknown function (DUF3458) Ig-like fold; This presumed domain is functionally uncharacterized. This domain is found in bacteria, archaea and eukaryotes. The domain has an Ig-like fold. This domain is found associated with pfam01433.


Pssm-ID: 463405 [Multi-domain]  Cd Length: 95  Bit Score: 147.66  E-value: 7.10e-42
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 449 GTPRLDVNGSYDADAQTYTLNFAQSCPATPESAEKQPFHIPVTLGLVGQQG-DLPLtlqgveqtetytDMVLEITESEQS 527
Cdd:pfam11940   1 GTPRVTVSDSYDAAAGTYTLTLSQTTPPTPGQPEKQPLHIPIRIALLDPNGqELAL------------ERVLELTEAEQT 68
                          90       100
                  ....*....|....*....|....*..
gi 2528347748 528 FVFENVTEQPVPSLLRDFSAPVKLDFP 554
Cdd:pfam11940  69 FTFEGVAEKPVPSLLRGFSAPVKLEYD 95
M1_APN_like cd09603
Peptidase M1 family similar to aminopeptidase N catalytic domain; This family contains mostly ...
35-445 1.58e-40

Peptidase M1 family similar to aminopeptidase N catalytic domain; This family contains mostly bacterial and some archaeal M1 peptidases with smilarity to the catalytic domain of aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease belonging to the M1 gluzincin family. APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and, in higher eukaryotes, is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation, thus considered a marker of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. APNs are also present in many pathogenic bacteria and represent potential drug targets. Some APNs have been used commercially, such as one from Lactococcus lactis used in the food industry. APN also serves as a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs have also been extensively studied as putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


Pssm-ID: 341066 [Multi-domain]  Cd Length: 410  Bit Score: 154.67  E-value: 1.58e-40
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748  35 ATVTATLKMRRNSHAgedapLLLHGIELELRELKIDGRvlDANEYYADAESLTI---EQVPAEFVLESTVFI--KPQENT 109
Cdd:cd09603    21 GTATITFRATQDLDS-----LQLDLVGLTVSSVTVDGV--PAAFFTHDGDKLVItlpRPLAAGETFTVTVRYsgKPRPAG 93
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 110 S----LEGLYKSDDMFCTQCEAEGFRkiTYY--LDRPDVMSEYTTTVVADKaGYpVLLSNGNPIDSGELDNGRHFVTWHD 183
Cdd:cd09603    94 YppgdGGGWEEGDDGVWTAGQPEGAS--TWFpcNDHPDDKATYDITVTVPA-GL-TVVSNGRLVSTTTNGGGTTTWHWKM 169
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 184 PFKKPSYLFALVAGDLEYIEDSfttmSGRNIELRIFVEEKDIDKCDHAMRSLKKSMAWDEEVYGrEYDLDIFMIVAVDAF 263
Cdd:cd09603   170 DYPIATYLVTLAVGRYAVVEDG----SGGGIPLRYYVPPGDAAKAKASFARTPEMLDFFEELFG-PYPFEKYGQVVVPDL 244
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 264 NmGAMENKGLNIFNTSAVLAKTETttdaafqrvEAIVAHEYFHNWSGNRVTCRDWFQLSLKEGFTVFRDAEFSADMGSrv 343
Cdd:cd09603   245 G-GGMEHQTATTYGNNFLNGDRGS---------ERLIAHELAHQWFGDSVTCADWADIWLNEGFATYAEWLWSEHKGG-- 312
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 344 vKRVEDVSLLRTAQFSEDAGPMAHPVQPASfieisNFYTLTVYEKGCEVVRMYHTLLGPELFREGSDLYFDRHDGQAATI 423
Cdd:cd09603   313 -ADAYRAYLAGQRQDYLNADPGPGRPPDPD-----DLFDRDVYQKGALVLHMLRNLLGDEAFFAALRAYLARYAHGNVTT 386
                         410       420
                  ....*....|....*....|...
gi 2528347748 424 EDFTRCMEEVSGRDLTQ-FKRWY 445
Cdd:cd09603   387 EDFIAAAEEVSGRDLTWfFDQWL 409
M1_APN cd09602
Peptidase M1 family including aminopeptidase N catalytic domain; This model represents the ...
25-444 1.68e-39

Peptidase M1 family including aminopeptidase N catalytic domain; This model represents the catalytic domain of bacterial and eukaryotic aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease belonging to the M1 gluzincin family. APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and, in higher eukaryotes, is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation, thus considered a marker of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. APNs are also present in many pathogenic bacteria and represent potential drug targets. Some APNs have been used commercially, such as one from Lactococcus lactis used in the food industry. APN also serves as a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs have also been extensively studied as putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


Pssm-ID: 341065 [Multi-domain]  Cd Length: 440  Bit Score: 152.28  E-value: 1.68e-39
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748  25 ELRVELMEEGATVTATLKMRRNSHAGeDAPLLLHGIELELRELKIDGRVLDANEYyaDAESLTIEQVPAEFVLESTVFIK 104
Cdd:cd09602    19 DLDLDLTEGAETFRGTVTIRFTLREP-GASLFLDFRGGEVKSVTLNGRPLDPSAF--DGERITLPGLLKAGENTVVVEFT 95
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 105 PQENTSLEGLYKSDDM------FCTQCEAEGFRKITYYLDRPDVMSEYTTTVVADKAGypVLLSNGNPIDSGELDNGRhf 178
Cdd:cd09602    96 APYSSDGEGLHRFVDPadgetyLYTLFEPDDARRVFPCFDQPDLKATFTLTVTAPADW--TVISNGPETSTEEAGGRK-- 171
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 179 vTWHdpFKK----PSYLFALVAGDLEYIEDSfttmsGRNIELRIFVEEKDIDK---CDHAMRSLKKSMAWDEEVYGREYD 251
Cdd:cd09602   172 -RWR--FAEtpplSTYLFAFVAGPYHRVEDE-----HDGIPLGLYCRESLAEYerdADEIFEVTKQGLDFYEDYFGIPYP 243
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 252 LDIFMIVAVDAFNMGAMENKGLNIFNTSAVLakTETTTDAAFQRVEAIVAHEYFHNWSGNRVTCRDWFQLSLKEGFtvfr 331
Cdd:cd09602   244 FGKYDQVFVPEFNFGAMENPGAVTFRESYLF--REEPTRAQRLRRANTILHEMAHMWFGDLVTMKWWDDLWLNESF---- 317
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 332 dAEFsadMGSRVVKRVEDVS------LLR--TAQFSEDAGPMAHPVQP------ASFieiSNFYTLTvYEKGCEVVRMYH 397
Cdd:cd09602   318 -ADF---MAAKALAEATPFTdawltfLLRrkPWAYRADQLPTTHPIAQdvpdleAAG---SNFDGIT-YAKGASVLKQLV 389
                         410       420       430       440
                  ....*....|....*....|....*....|....*....|....*...
gi 2528347748 398 TLLGPELFREGSDLYFDRHDGQAATIEDFTRCMEEVSGRDLTQFKR-W 444
Cdd:cd09602   390 ALVGEEAFRAGLREYFKKHAYGNATLDDLIAALDEASGRDLSAWADaW 437
Peptidase_M1_N pfam17900
Peptidase M1 N-terminal domain; This domain is found at the N-terminus of aminopeptidases from ...
15-191 1.83e-20

Peptidase M1 N-terminal domain; This domain is found at the N-terminus of aminopeptidases from the M1 family.


Pssm-ID: 465557 [Multi-domain]  Cd Length: 186  Bit Score: 89.71  E-value: 1.83e-20
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748  15 QPPNYlidttELRVELMEEGATVTATLKMRRNSHAGEDaPLLLHGIELELRELKIDGRV------LDANEYYADAESLTI 88
Cdd:pfam17900   1 VPEHY-----DLDLKIDLKNFTFSGSVTITLQLNNATN-VIVLHASDLTIRSISLSDEVtsdgvpADFTEDQKDGEKLTI 74
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748  89 eqVPAEFVLESTVFIKPQE-----NTSLEGLYKSDDM--------FCTQCEAEGFRKITYYLDRPDVMSEYTTTVVADKA 155
Cdd:pfam17900  75 --VLPETLNQTGPYTLEIEysgelNDSMTGFYRSTYTdngekkvlVTTQFEPTDARSAFPCFDEPSVKATFTISIIHPKD 152
                         170       180       190
                  ....*....|....*....|....*....|....*.
gi 2528347748 156 gyPVLLSNGNPIDSGELDNGRHFVTWHDPFKKPSYL 191
Cdd:pfam17900 153 --YTALSNMPVIASEPLENGWVITTFEQTPKMSTYL 186
leuko_A4_hydro TIGR02411
leukotriene A-4 hydrolase/aminopeptidase; Members of this family represent a distinctive ...
60-451 1.74e-19

leukotriene A-4 hydrolase/aminopeptidase; Members of this family represent a distinctive subset within the zinc metallopeptidase family M1 (pfam01433). The majority of the members of pfam01433 are aminopeptidases, but the sequences in this family for which the function is known are leukotriene A-4 hydrolase. A dual epoxide hydrolase and aminopeptidase activity at the same active site is indicated. The physiological substrate for aminopeptidase activity is not known.


Pssm-ID: 274120 [Multi-domain]  Cd Length: 602  Bit Score: 93.30  E-value: 1.74e-19
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748  60 IELELRELKIDGRVLDANEYYADAESLTIEQVPA---EFVLE---STV-------FIKPQENTSLEGLYksddMFcTQCE 126
Cdd:TIGR02411  57 QKVTINGLPADFAIGERKEPLGSPLTISLPIATSkndEFVLNisfSTTpkctalqWLNPEQTSGKKHPY----LF-SQCQ 131
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 127 AEGFRKITYYLDRPDVMSEYTTTVvadKAGYPVLLSnGNPIDSGELDNGRHFvtWHDPFKKPSYLFALVAGDLEyiedsf 206
Cdd:TIGR02411 132 AIHARSLFPCQDTPSVKSTYTAEV---ESPLPVLMS-GIRDGETSNDPGKYL--FKQKVPIPAYLIAIASGDLA------ 199
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 207 ttmsGRNIELR--IFVEEKDIDKC----DHAMRSLKKSMawdEEVYG----REYDLdifmIVAVDAFNMGAMENKGLNiF 276
Cdd:TIGR02411 200 ----SAPIGPRstVYSEPEQLEKCqyefENDTEKFIKTA---EDLIFpyewGQYDL----LVLPPSFPYGGMENPNLT-F 267
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 277 NTSAVLAKTETTTDaafqrveaIVAHEYFHNWSGNRVTCRDWFQLSLKEGFTVFrdaefsadMGSRVVKRVEDVsllRTA 356
Cdd:TIGR02411 268 ATPTLIAGDRSNVD--------VIAHELAHSWSGNLVTNCSWEHFWLNEGWTVY--------LERRIIGRLYGE---KTR 328
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 357 QFSEDAGPMAHPVQPASFIEISNFYTLTV---------------YEKGCEVVRMYHTLLG-PELFREGSDLYFDRHDGQA 420
Cdd:TIGR02411 329 HFSALIGWGDLQESVKTLGETPEFTKLVVdlkdndpddafssvpYEKGFNFLFYLEQLLGgPAEFDPFLRHYFKKFAYKS 408
                         410       420       430
                  ....*....|....*....|....*....|....*...
gi 2528347748 421 ATIEDFTRCM-------EEVSGRDLTQFKRWYSQAGTP 451
Cdd:TIGR02411 409 LDTYQFKDALyeyfkdkKKVDKLDAVDWETWLYSPGMP 446
M1_LTA4H cd09599
Peptidase M1 family including Leukotriene A4 hydrolase catalytic domain; This model represents ...
120-432 9.47e-19

Peptidase M1 family including Leukotriene A4 hydrolase catalytic domain; This model represents the N-terminal catalytic domain of leukotriene A4 hydrolase (LTA4H; E.C. 3.3.2.6) and the close homolog cold-active aminopeptidase (Colwellia psychrerythraea-type peptidase; ColAP), both members of the aminopeptidase M1 family. LTA4H is a bifunctional enzyme, possessing an aminopeptidase as well as an epoxide hydrolase activity. The two activities occupy different, but overlapping sites. The activity and physiological relevance of the aminopeptidase is poorly understood while the epoxide hydrolase converts leukotriene A4 (LTA4) into leukotriene B4 (LTB4), a potent chemotaxin that is fundamental to the inflammatory response of mammals. It accepts a variety of substrates, including some opioid, di- and tripeptides, as well as chromogenic aminoacyl-p-nitroanilide derivatives. The aminopeptidase activity of LTA4H is possibly involved in the processing of peptides related to inflammation and host defense. Kinetic analysis shows that LTA4H hydrolyzes arginyl tripeptides with high efficiency and specificity, indicating its function as an arginyl aminopeptidase. Thermodynamic characterization using different biophysical methods shows that structurally distinct inhibitors of the LTA4H occupy different regions of the binding site; while some (RB202, ARM1 and SC57461A) bind to the hydrophobic hydrolase side, both bestatin and captopril are located at the hydrophilic peptidase side. LTB4H overexpression is associated with different pathological conditions and diseases such as cystic fibrosis, coronary heart disease, sepsis, shock, connective tissue disease, and chronic obstructive pulmonary disease. It is also overexpressed in certain human cancers, and has been identified as a functionally important target for mediating anticancer properties of resveratrol, a well-known red wine polyphenolic compound with cancer chemopreventive activity.


Pssm-ID: 341062 [Multi-domain]  Cd Length: 442  Bit Score: 89.82  E-value: 9.47e-19
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 120 MFcTQCEAEGFRKITYYLDRPDVMSEYTTTVVADKaGYPVLLSNGNPIDSGELDNGRHfvTWHDPFKKPSYLFALVAGDL 199
Cdd:cd09599   127 LF-TQCQAIHARSLFPCQDTPSVKSTYSATVTVPK-GLTALMSALRTGEKEEAGTGTY--TFEQPVPIPSYLIAIAVGDL 202
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 200 EYiedsfttmsgRNIELRIFV--EEKDIDKCDHAMRSLKKSMAWDEEVYGR----EYDldifMIVAVDAFNMGAMENKGL 273
Cdd:cd09599   203 ES----------REIGPRSGVwaEPSVVDAAAEEFADTEKFLKAAEKLYGPyvwgRYD----LLVLPPSFPYGGMENPCL 268
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 274 nIFNTSAVLAKTETTTDaafqrveaIVAHEYFHNWSGNRVTCRDWFQLSLKEGFTVF--RdaefsadmgsRVVKRV--ED 349
Cdd:cd09599   269 -TFATPTLIAGDRSLVD--------VIAHEIAHSWSGNLVTNANWEHFWLNEGFTVYleR----------RILERLygEE 329
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 350 vsllrTAQFSEDAGpMAHPVQPASFIEISNFYTLTV----------------YEKGCEVVRMYHTLLGPELF----REgs 409
Cdd:cd09599   330 -----YRQFEAILG-WKDLQESIKEFGEDPPYTLLVpdlkgvdpddafssvpYEKGFQFLYYLEQLGGREVFdpflRA-- 401
                         330       340
                  ....*....|....*....|...
gi 2528347748 410 dlYFDRHDGQAATIEDFTRCMEE 432
Cdd:cd09599   402 --YFKKFAFQSIDTEDFKDFLLE 422
M1_APN_like cd09604
Peptidase M1 family similar to aminopeptidase N catalytic domain; This family contains ...
134-445 1.51e-18

Peptidase M1 family similar to aminopeptidase N catalytic domain; This family contains bacterial M1 peptidases with smilarity to the catalytic domain of aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease belonging to the M1 gluzincin family. APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and, in higher eukaryotes, is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation, thus considered a marker of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. APNs are also present in many pathogenic bacteria and represent potential drug targets. Some APNs have been used commercially, such as one from Lactococcus lactis used in the food industry. APN also serves as a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs have also been extensively studied as putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


Pssm-ID: 341067 [Multi-domain]  Cd Length: 440  Bit Score: 89.26  E-value: 1.51e-18
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 134 TYYLDrpdvMSEYTTTVVADKaGYpVLLSNGNPIDSGELDNGR---HFVTW--HDpfkkpsylFALVAGDlEYIEDSFTt 208
Cdd:cd09604   155 FFYSD----FGDYDVTITVPK-NY-VVAATGELQNPEEVLDGTktwHFKAEnvRD--------FAWAASP-DFVVDAAT- 218
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 209 msGRNIELRIFVEEKDIDKCDHAMRSLKKSMAWDEEVYGrEYDLDIFMIVAVDAFNmGAMENKGLnIFNTSavlaktetT 288
Cdd:cd09604   219 --VDGVTVNVYYLPENAEAAERALEYAKDALEFFSEKFG-PYPYPELDVVQGPFGG-GGMEYPGL-VFIGS--------R 285
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 289 TDAAFQRVEAIVAHEYFHNW----SGNrvtcrD-----WfqlsLKEGFTVFRDAEFSADMGSRVVKRVEDVSLLRTAQFS 359
Cdd:cd09604   286 LYDPKRSLEGVVVHEIAHQWfygiVGN-----DerrepW----LDEGLATYAESLYLEEKYGKEAADELLGRRYYRAYAR 356
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2528347748 360 EDAGPMAhpvQPASFIEISNFYTLTVYEKGcevVRMYHTL---LGPELFREGSDLYFDRHDGQAATIEDFTRCMEEVSGR 436
Cdd:cd09604   357 GPGGPIN---LPLDTFPDGSYYSNAVYSKG---ALFLEELreeLGDEAFDKALREYYRRYKFKHPTPEDFFRTAEEVSGK 430
                         330
                  ....*....|
gi 2528347748 437 DLTQF-KRWY 445
Cdd:cd09604   431 DLDWFfRGWL 440
 
Blast search parameters
Data Source: Precalculated data, version = cdd.v.3.21
Preset Options:Database: CDSEARCH/cdd   Low complexity filter: no  Composition Based Adjustment: yes   E-value threshold: 0.01

References:

  • Wang J et al. (2023), "The conserved domain database in 2023", Nucleic Acids Res.51(D)384-8.
  • Lu S et al. (2020), "The conserved domain database in 2020", Nucleic Acids Res.48(D)265-8.
  • Marchler-Bauer A et al. (2017), "CDD/SPARCLE: functional classification of proteins via subfamily domain architectures.", Nucleic Acids Res.45(D)200-3.
Help | Disclaimer | Write to the Help Desk
NCBI | NLM | NIH